Coley Pharmaceutical Group Announces $16.9 Million Research Contract From NIH for Development of New Vaccine Adjuvants for Biodefense
WELLESLEY, Mass. -- Coley Pharmaceutical Group, Inc. announced it has been awarded a $16.9 million, five-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH), to support the development of novel immune-activating drugs for defense against bioterror agents.
Entitled "Innate Immune Receptors and Adjuvant Discovery," this contract will be used to expand Coley's proprietary line of TLR Therapeutic products, focusing on basic research and preclinical studies of novel immunostimulatory compounds targeting Toll-like receptors.
Toll-like receptors (TLR's) are a family of receptors found on immune cells that are understood to direct immune response by detecting and recognizing specific classes of pathogens. Coley has previously shown that its TLR Therapeutics targeting TLR9 can stimulate protective immunity against potential bioterror germs such as anthrax. Coley has received two earlier government awards for the discovery and development of advanced biodefense vaccine adjuvants and therapeutics. Together with prior awards, the new contract brings the total committed biodefense funding for Coley to $35 million.
"We have made tremendous progress in the last few years in demonstrating the potential of Coley's immune stimulants to protect against lethal doses of most potential bioterror agents," said Arthur Krieg, MD, senior vice president, R&D, who will be leading Coley's research efforts under the contract. "This contract will facilitate the expansion of our research programs beyond TLR9 agonists to additional targets that activate the immune system in different ways. We believe our research efforts from this and prior grants will enable us to fine-tune potential products designed to defend against infectious agents with or without specific vaccines by regulating immune function."
Source: Coley Pharmaceutical Group
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.
